Clinical Trial Update: Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for recombinant erythropoietin aimed at neuroprotection in very preterm infants, involving Phase 1 and Phase 2 studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intraventricular Hemorrhage
• Periventricular Leukomalacia
• Retinopathy of Prematurity

Drugs mentioned

• Recombinant erythropoietin (erythropoietin)

Snippet

Sponsor: China Medical University Hospital | Conditions: Infant, Premature, Leukomalacia, Periventricular | Phase 1, Phase 2 | Status: UNKNOWN